1.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0359-08-HMO-CTIL, NCT00722228
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CT/07.07, NCT00750386
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ITL-002-CRYO, NCT00861107
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX1401-01, NCT00948961
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAR\TAXHY, NCT00189566
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IOSI-RO0402, RO0402, NCT00637637
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SC-126639, NCT00721890
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.26, NCT00748709
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: TASMC - 08 - BC - 270 - CTIL, NCT00781209
|
|
10.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UVACC-SCC-0102, WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
|
|
11.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2007.120, NCT00637390
|
|
12.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARRAY-380-101, NCT00650572
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX-1307-01, NCT00709462
|
|
14.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_501, NCT00749502
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL147-003, NCT00756847
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HBS601, NCT00765973
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MI-CP177, NCT00796055
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ATDTRPST0802, NCT00800345
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 05-409, NCT00821652
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 62242-003, NCT00848510
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DOX_2I_1476_09, NCT00862355
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCNONCO200902, NCT00982631
|
|
23.
|
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TAMC 3H04, NCT00160472
|
|
24.
|
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0035, 08-C-0035, NCT00658424
|
|
25.
|
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: F080328006/UAB0802, ROI CA 123197-01, NCT00711932
|
